Thrombotic thrombocytopenic purpura secondary prevention

Jump to navigation Jump to search

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura secondary prevention

CDC on Thrombotic thrombocytopenic purpura secondary prevention

Thrombotic thrombocytopenic purpura secondary prevention in the news

Blogs on Thrombotic thrombocytopenic purpura secondary prevention

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Effective measures for the secondary prevention of TTP include: prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions.

Secondary Prevention

Effective measures for the secondary prevention of TTP is prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions. Patients who had TTP should be obsereved for signs and symptoms of relapse.[1]

References

  1. Scully, Marie; Hunt, Beverley J.; Benjamin, Sylvia; Liesner, Ri; Rose, Peter; Peyvandi, Flora; Cheung, Betty; Machin, Samuel J. (2012). "Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies". British Journal of Haematology. 158 (3): 323–335. doi:10.1111/j.1365-2141.2012.09167.x. ISSN 0007-1048.

Template:WH Template:WS